Age-related macular degeneration (AMD) is the leading cause of blindness after 50 years in industrialized countries, compromising daily activities and reducing quality of life. And whose treatment is one of the first health expenditures. Since September 2015, Bevacizumab, which does not have marketing authorization in AMD, has been given a temporary recommendation for use. Studies in other countries have shown that bevacizumab is cost-effective in the treatment of AMD compared to other anti-VEGF therapies used.
Naive neovascular AMD form of retro localization foveal, unilateral or bilateral (one eye per patient will be studied),
Patients to be treated with intravitreous injections of Bevacizumab or Ranibizumab or Aflibercept,
Patient using effective contraception if he is of childbearing age
Patient informed and not having made his opposition to the research,
Previous or current treatment of AMD by intravenous injection of anti-VEGF or surgery dating less than 2 months in the studied eye,
Contraindications to the taking of Bevacizumab or Ranibizumab or Aflibercept,
Aphakia in the studied eye,
Fibrosis or retrofoveolar retinal atrophy of the eye studied,
Patients over 50 years of age with a naive neovascular AMD form with a retro-fleeal, unilateral or bilateral location, to be treated with intravitreous injections of Bevacizumab or Ranibizumab or Aflibercept according to the practice of each service
Cohort
Prospective
Not listed
Cost-utility analysis of the modalities of management of neovascular age-related macular degeneration
Using a probabilistic Markov model
Micro-costing type evaluation of packaging of Intravitreal injections of Bevacizumab in pharmacy hospital.
Costs of packaging of Intravitreal injections of Bevacizumab in pharmacy hospital (flasks of Bevacizumab, materials, personal, infrastructure, conservation)
Quality of life coefficient: HUI 3 questionnaire
Quality of life will be estimated using the HUI 3 questionnaire and corresponding value-set
Click on the lead sponsor to view all of their trials.
